Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.33 on Friday. Oragenics has a 12 month low of $0.25 and a 12 month high of $7.74. The firm’s 50 day moving average is $0.33 and its 200 day moving average is $0.83. The stock has a market capitalization of $4.03 million, a PE ratio of -0.05 and a beta of 0.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.